Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000280606
Ethics application status
Approved
Date submitted
11/03/2014
Date registered
17/03/2014
Date last updated
6/07/2016
Type of registration
Prospectively registered

Titles & IDs
Public title
The dressing and securement of tunnelled, cuffed Central Venous Access Devices (CVADs), in acute care paediatrics: a pilot, randomised controlled trial.
Scientific title
Randomised controlled trial of tissue adhesive, combined securement and dressing product or external stabilisation devices versus standard care (bordered polyurethane) dressings to prevent central venous access device failure in paediatric acute care patients with tunnelled, cuffed central venous access devices: the CASCADE Junior trial
Secondary ID [1] 284240 0
Nil
Universal Trial Number (UTN)
U1111-1154-3706
Trial acronym
The CASCADE Junior Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Central venous access device failure prior to completion of therapy 291352 0
Condition category
Condition code
Public Health 291716 291716 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Patients in this study have central venous access devices (CVADs) used in medical, surgical, anaesthetic and intensive care departments, and only paediatric patients. Consenting parents or legal guardians, and patients (if appropriate) will have their tunnelled, cuffed CVADs secured with one of the following randomly assigned dressings and securements:

Arm 1: Tissue Adhesive (TA) is a medical grade 'superglue'
(cyanoacrylate) used mainly to close skin acerations/wounds as an alternative to sutures and staples. A bordered polyurethane dressing will also be applied.

Arm 2: Sutureless Stabilisation Device (SSD) have a large adhesive padded footplate with locking clasp made of hard plastic or velcro. SSD are used in addition to bordered polyurethane.

Arm 3: Combined securement and dressing product: extra-reinforced borders, with an absorbent layer around the polyurethane claimed to ‘wick’ moisture away from the wound

Arm 4 (Control): Bordered polyurethane (BPU) dressings involve a clear polyurethane with an added external adhesive border of foam or cloth fabric. They will also have their CVAD secured with prolene sutures.

The randomly allocated dressing will be applied until completion of therapy, hospital discharge or at 4 weeks. The dressing will be applied at CVAD insertion and then changed every 7 days, or on disruption of the dressing integrity.
Intervention code [1] 288948 0
Prevention
Intervention code [2] 288970 0
Treatment: Devices
Comparator / control treatment
Arm 4 (Control): Bordered polyurethane (BPU) dressings involve a clear polyurethane with an added external adhesive border of foam or cloth fabric. They will also have their CVAD secured with prolene sutures.
Control group
Active

Outcomes
Primary outcome [1] 291659 0
CVAD failure and complication: Composite measure of any reason for unplanned CVAD removal, prior to the completion of therapy. This includes (i) Central Line-Associated Bloodstream Infection (CLABSI); (ii) local infection of skin or sutures: (iii) dislodgement: (iv) occlusion (v) CVAD breakage and (vi) venous thrombosis. The primary outcome of device failure is an objective measure, assigned by clinical staff (not research staff or investigators). This is routine clinical practice. Research staff will collect the primary endpoint from the medical records with additional information obtained from the clinical staff/patients if required
Timepoint [1] 291659 0
At time of CVAD removal, 4 weeks, or hospital discharge
Primary outcome [2] 291660 0
Feasibility of a full efficacy trial as established by:
*Eligibility: Percentage of patients screened that are eligible;
*Recruitment: Percentage of eligible patients who agree to enrol;
*Retention and attrition: Percentage of participants who are lost to follow-up or withdraw from study;
*Protocol adherence: Percentage of participants who receive their allocated treatment throughout their study participation;
*Missing data: Percentage of data missed during study data collection;
*Parent and healthcare staff satisfaction and acceptability: Using a semi-structured survey; and
*Sample size estimates: a reduction in all-case CVAD failure (defined in the secondary outcomes) by at least 5% in the experimental arms, in comparison to standard care.
Timepoint [2] 291660 0
At conclusion of study
Secondary outcome [1] 307243 0
Central line-associated bloodstream infection (CLABSI):
A laboratory-confirmed bloodstream infection (LCBI) in a patient who had a central line within the 48 hour period before the development of the BSI, and that is not related to an infection at another site. The CLABSI must meet one of the following criteria of LCBI: Criterion 1: Patient has a recognised pathogen cultured from one or more blood cultures and Organism cultured from blood is not related to an infection at another site. OR Criterion 2: Patient has at least one of the following signs or symptoms: fever (greater than 38 degrees C), chills, or hypotension, and signs and symptoms and positive laboratory results are not related to an infection at another site, and common skin contaminant* is cultured from two or more blood cultures drawn on separate occasions. Examples of common skin contaminants: diphtheroids [Corynebacterium spp.], Bacillus [not B. anthracis] spp., Propionibacterium spp., coagulasenegative staphylococci [including S. epidermidis], viridans group streptococci, Aerococcus spp., Micrococcus spp.
Timepoint [1] 307243 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [2] 307244 0
Local infection of the skin:
Purulent discharge, or redness extending 1cm beyond the site that prompts clinician to order removal and commence antimicrobial therapy.
Timepoint [2] 307244 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [3] 307245 0
Dislodgement:
Partial: any post-insertion change in the length of the CVAD body from the hub to the CVAD tip, as measured by the catheter marking in closest approximation to hub.
Total: CVAD body completely leaves the vein, or must be removed
because CVAD tip is no longer in the superior vena cava (diagnosed by XRay/leakage from site on injection/clinician diagnosis)
Timepoint [3] 307245 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [4] 307246 0
Occlusion:
>/=1 lumen unable to be flushed/aspirated, diagnosed by treating
clinician
Timepoint [4] 307246 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [5] 307247 0
CVAD breakage:
Visible split in CVAD material diagnosed by treating clinician
Timepoint [5] 307247 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [6] 307248 0
Dressing/securement failure:
Early replacement before seven days for loose, soiled or missing
dressings
Timepoint [6] 307248 0
At seven days after dressing application.
Secondary outcome [7] 307249 0
CVAD dwell time, and dressing dwell time:
Time in hours from insertion/application until removal
Timepoint [7] 307249 0
At the time of CVAD removal.
Secondary outcome [8] 307250 0
Parentand staff satisfaction and acceptability ranked on a 10-point scale
Timepoint [8] 307250 0
At time of CVAD removal, 4 weeks, or hospital discharge
Secondary outcome [9] 317318 0
Venous thrombosis: Development of thrombosed vessel (partial or complete) at the CVAD site diagnosed radiologically as requested by the treating clinician in a symptomatic patient;
Timepoint [9] 317318 0
At time of CVAD removal, hospital discharge or 4 weeks
Secondary outcome [10] 317319 0
Cost effectiveness: Estimates of direct product costs, healthcare resource utilisation (including additional equipment, staff time) and failure-associated resource usage using previously established cost estimates;
Timepoint [10] 317319 0
At study completion
Secondary outcome [11] 317320 0
Safety: Skin complications including skin rash, skin tears, blisters, pruritis, local or systemic allergic reaction during study as assessed by clinical staff
Timepoint [11] 317320 0
CVAD removal, hospital discharge or 4 weeks after insertion

Eligibility
Key inclusion criteria
Inclusion criteria:
*Patient requires the insertion of a tunnelled, cuffed CVAD for >24 hours;
*Will remain in admitted to the RCH or Lady Cilento Childrens Hospital for >24 hours; and
*Parent or legal guardian, and child if developmentally appropriate, gives informed consent.
Minimum age
No limit
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:
*Non-tunnelled, peripherally inserted, dialysis, or implanted CVADs or pulmonary artery catheters;
*Current bloodstream infection;
*CVAD to be inserted through diseased, burned or scarred skin;
*Allergy to study product; and
*Previous study enrolment in this admission to hospital.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The research nurse (RN) will screen patients daily (screening log kept), gain informed consent, and perform randomisation. The RN will have the study products in pre-packs and liaise closely with the ordering and
inserting surgeon. All elligible patients (or
their representative) will be approached for written informed consent by the RN or inserter. If this is given, the staff member use a centralised web-based randomisation service. Allocation is fully concealed until the patient is randomised.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated. Randomisation will be in a 1:1:1:1 ratio between the four study groups. Permuted blocks in randomly varied sizes will be used
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
All randomised patients will be analysed by intention to treat, regardless of treatment received. The patient is the unit of measurement with one CVAD per patient.
Feasibility outcomes will be described using descriptive statistics including mean, median, range, IQR, counts and percentages. Comparability of groups at baseline will be assessed using clinical parameters. Relative incidence rates of CVAD and dressing failure per 100 devices and per 1,000 device days with 95% confidence intervals (CIs) will summarise the impact of each dressing, and to test
difference between groups. Kaplan-Meier survival curves (with log rank Mantel-Cox test) will compare CVAD failure over time. Secondary endpoints including CVAD dwell-time, costs, dislodgement, occlusion, CVAD breakage, patient/staff satisfaction scores and adverse events will be compared between groups using parametric/nonparametric techniques as appropriate. Data will be
exported into PASW 18.0 (SPSS Inc, Chicago, IL). Prior to analysis, data cleaning of outlying figures, missing, and implausible data will be
undertaken, and a random 5% sample of source data rechecked. All attempts will be made to collect the primary endpoint. Missing data will be modelled for best- and worst-case outcomes to assess for effect on overall results. A per-protocol analysis will assess the effect of protocol
violations. P values of <0.05 will be considered significant.

Sample size and study power: This is a pilot study to gain information to prepare for an efficacy trial. Twenty participants per study arm will be recruited - totaling 80 participants.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/04/2014
Actual
2/06/2014
Date of last participant enrolment
Anticipated
2/05/2016
Actual
2/05/2016
Date of last data collection
Anticipated
13/05/2016
Actual
13/05/2016
Sample size
Target
80
Accrual to date
Final
48
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 3299 0
Royal Children's Hospital - Herston
Recruitment hospital [2] 3300 0
Lady Cilento Children's Hospital - South Brisbane

Funding & Sponsors
Funding source category [1] 288872 0
University
Name [1] 288872 0
Griffith University
Country [1] 288872 0
Australia
Funding source category [2] 290489 0
Commercial sector/Industry
Name [2] 290489 0
Centurion Medical Products
Country [2] 290489 0
United States of America
Primary sponsor type
University
Name
Griffith University
Address
Nathan Campus,
170 Kessels Road,
Nathan, QLD 4111
Country
Australia
Secondary sponsor category [1] 287566 0
None
Name [1] 287566 0
Nil
Address [1] 287566 0
Nil
Country [1] 287566 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 290699 0
Children's Health Services, Queensland
Ethics committee address [1] 290699 0
Ethics committee country [1] 290699 0
Australia
Date submitted for ethics approval [1] 290699 0
Approval date [1] 290699 0
14/11/2013
Ethics approval number [1] 290699 0
HREC/13/QRCH/181
Ethics committee name [2] 290700 0
Griffith University
Ethics committee address [2] 290700 0
Ethics committee country [2] 290700 0
Australia
Date submitted for ethics approval [2] 290700 0
Approval date [2] 290700 0
20/02/2014
Ethics approval number [2] 290700 0
NRS/10/14/HREC

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 46854 0
Ms Amanda Ullman
Address 46854 0
NHMRC Centre for Research Excellence in Nursing, Griffith University
170 Kessels Rd, Nathan, QLD 4111
Country 46854 0
Australia
Phone 46854 0
+61 7 3735 7854
Fax 46854 0
Email 46854 0
[email protected]
Contact person for public queries
Name 46855 0
Amanda Ullman
Address 46855 0
NHMRC Centre for Research Excellence in Nursing, Griffith University
170 Kessels Rd, Nathan, QLD 4111
Country 46855 0
Australia
Phone 46855 0
+61 7 3735 7854
Fax 46855 0
Email 46855 0
[email protected]
Contact person for scientific queries
Name 46856 0
Amanda Ullman
Address 46856 0
NHMRC Centre for Research Excellence in Nursing, Griffith University
170 Kessels Rd, Nathan, QLD 4111
Country 46856 0
Australia
Phone 46856 0
+61 7 3735 7854
Fax 46856 0
Email 46856 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseCentral venous Access device SeCurement and Dressing Effectiveness (CASCADE) in paediatrics: Protocol for pilot randomised controlled trials.2016https://dx.doi.org/10.1136/bmjopen-2016-011197
EmbaseInnovative dressing and securement of tunneled central venous access devices in pediatrics: A pilot randomized controlled trial.2017https://dx.doi.org/10.1186/s12885-017-3606-9
N.B. These documents automatically identified may not have been verified by the study sponsor.